Sodium phenylbutyrate
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Combined D,L-2-hydroxyglutaric Aciduria
Conditions
Combined D,L-2-hydroxyglutaric Aciduria
Trial Timeline
Jul 30, 2025 → Dec 1, 2027
NCT ID
NCT07125066About Sodium phenylbutyrate
Sodium phenylbutyrate is a phase 1 stage product being developed by Zevra Therapeutics for Combined D,L-2-hydroxyglutaric Aciduria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07125066. Target conditions include Combined D,L-2-hydroxyglutaric Aciduria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07125066 | Phase 1 | Recruiting |
| NCT06773026 | Phase 2 | Recruiting |
Competing Products
6 competing products in Combined D,L-2-hydroxyglutaric Aciduria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pravafen + Pravastatin + Fenofibrate | Shionogi | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Tremelimumab + Durvalumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Vaxelis™ | Merck | Approved | 85 |
| Leios/Alesse | Pfizer | Pre-clinical | 22 |